The stock market is witnessing a historic session of “haves and have-nots” this Wednesday, August 19, 2026. While the S&P 500 (7,723.28, +0.41%) and NASDAQ (26,403.06, +0.43%) are grinding higher, the real story lies in the violent rotation occurring under the surface. Billions in capital are aggressively shifting from legacy chipmakers to custom AI silicon, while a breakthrough in cancer treatment has ignited a frantic short squeeze in the biotech sector.

Below is your comprehensive, data-driven guide to the 10 Top Trending Stocks Today. We’ve stripped away the noise to bring you the raw numbers, the “why” behind the moves, and the critical price levels you need to watch for tomorrow.

Market Snapshot: August 19, 2026

1. Moderna Inc (MRNA): The “Vaccine Victory” Candle

Status: 🚀 Top Gainer | Sector: Biotechnology

Moderna is the undisputed king of the market today, executing a parabolic move that has left short-sellers trapped. The catalyst is a confirmed Phase 3 success for its mRNA cancer vaccine (mRNA-4157) in combination with Keytruda, showing a dramatic improvement in recurrence-free survival for melanoma patients.

Forecast & Technical Analysis:

• Trend: Parabolic Breakout. The stock has cleared all resistance levels from 2024-2025.
• Resistance: $160.00 (Psychological) and $175.00 (Fibonacci extension).
• Support: $115.00 (Previous breakout zone).
• Analyst Outlook: The “INTerpath-001” trial data effectively re-rates Moderna from a “COVID stock” to a premier oncology play. Expect extreme volatility; a pullback to $130 is possible as day traders take profits, but the long-term trend has fundamentally shifted.

2. Marvell Technology (MRVL): The “Google AI” Coup

Status: 📈 Breakout | Sector: Semiconductors

Marvell is surging after announcing a strategic partnership with Google (Alphabet). The deal involves Google acquiring warrants for a $12.2B stake, incentivizing Marvell to produce custom TPU silicon for Google’s next-gen AI data centers. This is a direct blow to competitors like Broadcom.

Forecast & Technical Analysis:

• Trend: Bullish Reversal. Recovering from a multi-month consolidation.
• Resistance: $240.00 (Recent swing high).
• Support: $215.00 (20-day Moving Average).
• Analyst Outlook: This partnership validates Marvell’s “Custom Compute” thesis. Analysts are likely to revise price targets upward toward $275. Watch for a daily close above $240 to confirm the next leg up.

3. Candel Therapeutics (CADL): The Biotech Momentum Play

Status: 📈 Momentum | Sector: Biotechnology

Riding the sector-wide wave sparked by Moderna, Candel is breaking out. Freedom Broker raised its price target to $15.00 yesterday, citing the start of patient enrollment in its Phase III “AURORA” trial for non-small cell lung cancer. The market is pricing in a high probability of success for its viral immunotherapy platform.

Forecast & Technical Analysis:

• Trend: Blue Sky Breakout. Trading at all-time highs for the year.
• Resistance: None (Blue sky). Next target $15.00.
• Support: $11.50 (Former resistance).
• Analyst Outlook: Confirmed plans to file a BLA (Biologics License Application) by late 2026 provide a concrete timeline for value realization. This is a high-risk/high-reward “buy” on dips.

4. Cipher Mining (CIFR): The “Capital Crunch” Victim

Status: 📉 Sell-Off | Sector: Crypto Mining

Cipher is suffering from a “sell the news” reaction following its Q2 earnings, where it reported a net loss of $267.5 million. Investors are spooked by the soaring costs of its transition to High-Performance Computing (HPC) and the general weakness in Bitcoin mining profitability post-halving.

Forecast & Technical Analysis:

• Trend: Bearish Correction.
• Resistance: $17.00.
• Support: $14.50 (Critical level).
• Analyst Outlook: The stock looks “fully priced” according to valuation models. Unless Bitcoin rallies significantly or the company demonstrates better cost control, the path of least resistance is lower. Watch the $14.50 floor; if it breaks, $12.00 is in play.

5. Target Corp (TGT): The Retail Renaissance

Status: ✅ Earnings Winner | Sector: Retail

Target is defying the “recession” narrative. The retailer reported a “triple beat” (Earnings, Revenue, and Comps) this morning. CEO Michael Fiddelke’s strategy of aggressive price cuts on 5,000 items has successfully driven foot traffic back to stores, leading to a raise in full-year guidance.

Forecast & Technical Analysis:

• Trend: Bullish Continuation.
• Resistance: $165.00.
• Support: $152.00 (Gap fill).
• Analyst Outlook: This is a high-quality breakout. Institutions are accumulating shares as Target proves it can defend margins while lowering prices. A close above $160 would be extremely bullish for Q3.

6. Tempus AI Inc (TEM): The Profitable Pivot

Status: 🚀 Surge | Sector: Healthcare AI

Tempus AI is the day’s “fundamental surprise.” The stock is up over 13% after reporting its first-ever GAAP profit of $5.6 million. The market loves the shift from “cash burn” to “operating leverage,” especially as the company raised its 2026 revenue guidance to ~$1.6 billion.

Forecast & Technical Analysis:

• Trend: Aggressive Recovery. Breaking out of a downtrend.
• Resistance: $60.00.
• Support: $50.00.
• Analyst Outlook: The acquisition of Personalis for $1.5B caused some initial jitters, but the profitability milestone has overshadowed those concerns. Short-squeeze dynamics are in play here.

7. TeraWulf Inc (WULF): The “Growing Pains” Pullback

Status: 📉 Correction | Sector: Digital Infrastructure

Like Cipher, TeraWulf is being punished for a massive $940 million Q2 net loss, driven largely by one-time charges related to its debt restructuring and AI pivot. While the $19B lease deal with Anthropic is bullish long-term, the immediate sticker shock of the loss is driving retail capitulation.

Forecast & Technical Analysis:

• Trend: Short-Term Bearish.
• Resistance: $16.50.
• Support: $13.50.
• Analyst Outlook: The thesis remains intact (“nuclear-powered AI compute”), but the financials are messy. Smart money may wait for the stock to stabilize around $13.50-$14.00 before re-entering.

8. Broadcom Inc (AVGO): The “Displaced” Giant

Status: ⚠️ Warning | Sector: Semiconductors

Broadcom is the collateral damage of the Marvell-Google news. The market perceives the Google investment in Marvell as a direct threat to Broadcom’s near-monopoly on high-end custom AI accelerators (ASICs).

Forecast & Technical Analysis:

• Trend: Bearish Breakdown.
• Resistance: $380.00.
• Support: $350.00 (Critical psychological level).
• Analyst Outlook: This is a sentiment-driven overreaction, but “narrative breaks” can be powerful. If AVGO loses the $350 support, it could flush to $325. Contrarian value investors should be watching closely.

9. Merck & Co Inc (MRK): The “Keytruda” Booster

Status: 📈 Solid Gains | Sector: Pharmaceuticals

Merck is rallying in tandem with Moderna. As the owner of Keytruda, the successful trial results significantly extend the “tail” of its blockbuster drug, mitigating fears of the upcoming “patent cliff” in 2028. Analysts at JPMorgan raised their target to $150 today.

Forecast & Technical Analysis:

• Trend: Bullish Breakout.
• Resistance: $155.00.
• Support: $140.00.
• Analyst Outlook: A “Safe Haven” trade. The stock offers a yield and now renewed growth prospects. It is likely to grind higher slowly rather than spike further.

10. Iovance Biotherapeutics (IOVA): The Sympathy Trade

Status: 📈 Follow-Through | Sector: Biotechnology

Iovance hit a new 52-week high yesterday and is continuing its run today. Investors are betting that the success of Moderna/Merck’s cancer vaccine will spur M&A activity across the sector, making mid-cap oncology players like IOVA attractive buyout targets.

Forecast & Technical Analysis:

• Trend: Sector Momentum.
• Resistance: $8.00.
• Support: $7.00.
• Analyst Outlook: Highly speculative but showing immense relative strength. Keep a tight stop-loss at $7.00; if the biotech hype fades, this will be the first to drop.

Consolidated Data: Top 10 Trending Stocks (Aug 19, 2026)

Final Word: How to Trade Tomorrow

The market has handed traders a clear playbook: Long Innovation, Short Inefficiency.

• Watch MRNA: If it holds above $140, the squeeze isn’t over.
• Watch TGT: Institutional buying should support this well into the $160s.
• Caution: Avoid catching falling knives in the crypto miner space (CIFR, WULF) until their cash burn stabilizes.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.

About The Author

Nichole Miller

See author's posts